药物性肝损伤的风险管理。
Managing the risk of drug-induced liver injury.
机构信息
1] Hamner-University of North Carolina Institute for Drug Safety Sciences and Department of Medicine, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA [2] Department of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA.
出版信息
Clin Pharmacol Ther. 2013 Dec;94(6):629-31. doi: 10.1038/clpt.2013.182.
In clinical trials, bosentan was shown to cause significant drug-induced liver injury (DILI) in some patients. Because it is not possible to identify those at higher risk for DILI, all patients to be treated with bosentan must enroll in a program requiring documentation of liver blood testing before they can receive the drug. Because this program is costly and is perceived as onerous, a genetic test capable of identifying susceptible individuals would probably be rapidly adopted by physicians.
在临床试验中，波生坦已被证明会导致一些患者出现显著的药物性肝损伤（DILI）。由于无法识别出那些具有更高 DILI 风险的患者，所有接受波生坦治疗的患者都必须参加一个要求在接受药物治疗前记录肝脏血液检测的项目。由于该项目成本高昂且被认为繁琐，因此一种能够识别易感个体的基因检测方法可能会被医生迅速采用。
Zotero 插件